D-0120 / InventisBio - LARVOL DELTA

RT2C: Predicting Time-to-New Caries with Structured Dental Data Using RNN. (PubMed, J Dent Res) - "Data were extracted from 4 dental organizations, comprising 466,782 patients and 1,062,553 examination visits (D0120, D0150, D0145) between 2019 and 2023...RT2C models visit-indexed risk trajectories and predicted new caries occurrence by the subsequent visit, aligning with the preventive framework of CAMBRA. By integrating longitudinal EDR data, it adds value to existing CRA tools and supports proactive, personalized caries management."

Journal • Dental Disorders • Preventive care

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: InventisBio Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Gout • Inflammatory Arthritis • Rheumatology

Lessons Learned From Genetic Testing for Hearing Loss in the USA (ARO 2026) - "Coupled with clinician education, accessible genetic counseling, and integration into newborn hearing screening pathways, these strategies will greatly improve outcomes for individuals with hearing loss. Acknowledgement: This work was supported in part by National Institutes of Health—National Institute on Deafness and Other Communication Disorders grants R01 DC002842, DC003544, and DC012049."

Developmental Disorders • Otorhinolaryngology • COL11A1 • COL1A1 • SLC26A4

Long-Read Sequencing for Detection of STRC Variants (ARO 2026) - "This study demonstrates the potential of LRS to offer improvements in variant detection pipelines in the STRC region. However, LRS is expensive and is not simple. Region-specific expertise is essential for analysis and interpretation."

Otorhinolaryngology

Protein Biophysics-Informed Assessment of Genetic Variants in Hearing Loss (ARO 2026) - "Using deep learning protein structure prediction models, sequence-based genetic predictors, and biophysical evidence, we identified missense variants highly likely to lead to protein misfolding. Future work will link these data to patients who carry prioritized missense variants but did not receive a definitive genetic diagnosis for their hearing loss to determine whether variant classification can be upgraded from VUS to likely pathogenic. Acknowledgment: This research was supported in part by NIH-NIDCD R01 DC012049."

Otorhinolaryngology

IQGAP1 Deficiency Induces Progressive Hearing Loss With Early Onset (ARO 2026) - "Young Iqgap1-/- mice (1-month-old) display a significant sensorineural hearing loss as evidenced by increased ABR thresholds at the highest (24 kHz, 32 kHz) and lowest (6 kHz) frequencies, associated with a reduced amplitude of DPOAEs. These results demonstrate an essential role for IQGAP1 in cochlear physiology and support its requirement for the maintenance of hearing function and OHC survival during aging. Acknowledgment: This research was supported in part by NIH-NIDCD R01s DC002842, DC012049, and DC017955 (RJHS)."

Otorhinolaryngology • IQGAP1 • SLC26A4

Characterization of Lower Extremity Pain in Ambulatory Individuals After Stroke. (PubMed, Arch Phys Med Rehabil) - "Chronic lower extremity pain is associated with poorer perceptions of functional outcomes in ambulatory stroke survivors. Pain is more prevalent on the paretic side and is significantly associated with lower perceived mobility, participation in physical activity, and recovery. Comprehensive pain assessment and management should be prioritized in post-stroke rehabilitation."

Journal • Cardiovascular • Movement Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

DDintensity: Addressing imbalanced drug-drug interaction risk levels using pre-trained deep learning model embeddings. (PubMed, Artif Intell Med) - "Additionally, case studies on chemotherapeutic drugs, DB00398 (Sorafenib) and DB01204 (Mitoxantrone) used in oncology, were conducted to demonstrate the specificity and effectiveness of the this methods. Our approach demonstrates high scalability across DDI modalities, as well as the discovery of novel interactions. In summary, we introduce DDIntensity as a solution for imbalanced datasets in bioinformatics with pre-trained deep-learning embeddings."

Journal • Oncology

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: InventisBio Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Gout • Inflammatory Arthritis • Rheumatology

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (clinicaltrials.gov) - P2 | N=121 | Completed | Sponsor: InventisBio Co., Ltd | Recruiting ➔ Completed

Trial completion

Repurposing FDA-approved drugs for combating tigecycline resistance in Acinetobacter baumannii: in silico screening against BaeR protein. (PubMed, Mol Divers) - "Acinetobacter baumannii is becoming a gravely threatening nosocomial infection with a higher mortality rate. The per-residue interaction analysis confirmed that interactions with binding site residues were stable throughout the simulation. As a result of the study, four compounds, namely ZINC000003801919, DB01203, DB11217 and ZINC0000000056652, were identified as efficient candidates to deal with antimicrobial resistance in A. baumannii."

FDA event • Journal • Infectious Disease

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: InventisBio Co., Ltd | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Combination therapy • Trial completion date • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (clinicaltrials.gov) - P2 | N=121 | Recruiting | Sponsor: InventisBio Co., Ltd | Phase classification: P2b ➔ P2 | Trial primary completion date: Dec 2023 ➔ Apr 2024

Phase classification • Trial primary completion date

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: InventisBio Co., Ltd | Trial completion date: Apr 2024 ➔ Dec 2024 | Trial primary completion date: Jan 2024 ➔ Jul 2024

Combination therapy • Trial completion date • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (clinicaltrials.gov) - P2b | N=121 | Recruiting | Sponsor: InventisBio Co., Ltd | N=90 ➔ 121

Enrollment change

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: InventisBio Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Gout • Inflammatory Arthritis • Rheumatology

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (clinicaltrials.gov) - P2b | N=90 | Recruiting | Sponsor: InventisBio Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open

Evaluation of PK and Safety of D-0120 and Allopurinol (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: InventisBio Co., Ltd | Active, not recruiting ➔ Completed

Trial completion

Phase II Study to Evaluate Efficacy and Safety of D-0120 Administered in Combination With Allopurinol in Subjects With Gout (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: InventisBio Co., Ltd

Combination therapy • New P2 trial • Gout • Inflammatory Arthritis • Rheumatology

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (clinicaltrials.gov) - P2b | N=90 | Not yet recruiting | Sponsor: InventisBio Co., Ltd

New P2b trial

D-0120 Safety and PK/PD Study in China (clinicaltrials.gov) - P1/2 | N=52 | Completed | Sponsor: InventisBio Co., Ltd | Recruiting ➔ Completed | Trial primary completion date: Jun 2021 ➔ Dec 2021

Trial completion • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology

Evaluation of PK and Safety of D-0120 and Allopurinol (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: InventisBio Co., Ltd | Trial completion date: Apr 2022 ➔ Jul 2022

Trial completion date

Seawater fungi-derived compound screening to identify novel small molecules against dengue virus NS5 methyltransferase and NS2B/NS3 protease. (PubMed, Inform Med Unlocked) - "Both licensed medications, estramustine (DB01196) and quinestrol (DB04575), were found to be similar to Chevalone E, with prediction scores of 0.818 and 0.856, respectively. In addition, cholic acid (DB02659), acitretin (DB00459), and mupirocin (DB00410) are similar to Sterolic acid, zidovudine (DB00495), imipenem (DB01598), and nadolol (DB01203) are similar to Brocazine A, and budesonide (DB01222) and colchicine (DB01394) are related to Brevione K. These findings suggest that these could be feasible dengue virus treatment options, meaning that more research is needed."

Journal • Dengue Fever • Infectious Disease • Novel Coronavirus Disease

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: InventisBio Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

D-0120 Safety and PK/PD Study in China (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: InventisBio Inc.; Trial completion date: Jul 2021 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology